Egyptian Cancer Society – ECS shared a post on LinkedIn:
“Emerging Clinical Evidence in AML
New findings from the Phase 1/2 ASCERTAIN-V trial suggest that an all-oral regimen of decitabine/cedazuridine plus venetoclax may offer a promising treatment option for patients with newly diagnosed AML who are ineligible for intensive chemotherapy.
Sharing this important update with our oncology community.”
Other posts about Egyptian Cancer Society on OncoDaily.